MedTrace Logo

Empowering Patients On Choices for Renal Replacement Therapy (Aim 3) (EPOCH-RRT)

NCT02488317 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2017-05-10

Study results available
· View outcomes & findings →

Summary

Empowering Patients On Choices for Renal Replacement Therapy (EPOCH-RRT) study seeks to identify factors that matter the most to patients with kidney disease and study how they are impacted by different types of dialysis. The inclusion of patients, caregivers, and patient advocacy organizations as research partners will assure that the study addresses questions of greatest relevance to patients facing the need for dialysis.

For Aim 3, the investigators are going to compare measures related to the decision-making process between patients receiving and not receiving a decision aid focusing on Peritoneal Dialysis and Hemodialysis.

Conditions

Interventions

OTHER

Decision Aid

Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.

Sponsors & Collaborators

  • University of Michigan

    collaborator OTHER

  • Henry Ford Health System

    collaborator OTHER

  • National Kidney Foundation, United States

    collaborator OTHER

  • American Association of Kidney Patients

    collaborator OTHER

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • Arbor Research Collaborative for Health

    lead OTHER

Principal Investigators

  • Francesca Tentori, MD, MS · Arbor Research Collaborative for Health

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02488317 on ClinicalTrials.gov